GBA1 and neurodegenerative disease: A substantial majority (70.7%–94.8%) felt that results regarding pathogenic or likely pathogenic variants in a gene known to cause PD or other neurodegenerative diseases, as well as variants known to increase the risk of PD (e.g., GBA1 variants) should be returned.